The DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index; 20 of the 29 sources its claims cite were checked for support.
Effect of l-arginine compared to placebo on sexual function in women with major depressive disorder: a randomized controlled trial
Open accessAbstract
Background: While some evidence suggests that l-arginine may improve sexual function and alleviate depression, it has not been investigated in women with depression to assess both its effects on the depression and sexual function concurrently. Methods: Patients who had received a diagnosis of major depressive disorder, as determined by predetermined inclusion and exclusion criteria, were enrolled in this triple-blind clinical trial. Patients were divided into two groups: group A, received L-arginine 1 gram twice daily, and group B, received a placebo for four weeks. They were evaluated at baseline, after four and eight weeks with the Hamilton Depression Rating Scale (HDRS), and Rosen’s questionnaire or Female Sexual Function Index (FSFI). Results: A decrease in the severity of depression was observed in all patients, which was determined due to Hamilton’s questionnaire (P-value < 0.001). During the time in group A, FSFI increased. Based on the FSFI questionnaire, they had improvement in some domains, including the lubrication index and orgasm index, which significantly changed in the eighth week compared to the baseline (P-value < 0.05). However, these two indicators did not change statistically significantly compared to the placebo group. Conclusion: L-arginine supplementation can improve sexual function, particularly lubrication and orgasm, and mood in women with depression, with minimal side effects observed. Additional research is necessary to validate these results by examining the effects of higher dosages, extended durations, and larger populations of depressed patients. Trial registration: Iranian Registry of Clinical Trial: IRCT20100127003210N26. © The Author(s) 2024.
Overview
CoChat Summary
TL;DR
This triple-blind randomized trial in women with major depressive disorder found that adding l-arginine 1 g twice daily for 4 weeks improved some sexual function subdomains within the treatment group, especially lubrication and orgasm, but not significantly versus placebo. Depression severity decreased over time in both groups, and the added l-arginine did not produce a statistically significant between-group benefit.
Key findings
- The study enrolled 32 women with major depressive disorder: 16 received l-arginine and 16 received placebo.
- In the l-arginine group, FSFI lubrication and orgasm indices improved significantly over time, with reported p-values of 0.032 and 0.023, respectively; however, these changes were not statistically significant compared with placebo.
- Depression severity measured by HDRS decreased significantly over time in both groups (P_time < 0.001), but the intervention had no significant between-group effect on HDRS changes (P_time*group < 0.001 is reported for interaction over time, yet the paper also states no significant difference between groups at measured time points).
- In multivariable GEE analysis, there was no significant association between treatment group and changes in HDRS, FSFI, or FSFI subgroups; the average FSFI difference for l-arginine versus placebo was β = 0.37, 95% CI -4.99 to 5.74, P = 0.891.
Methods
- Triple-blind, randomized clinical trial conducted from August 2022 to August 2023 at the psychiatric departments of Ayatollah Taleghani Hospital, Tehran, Iran.
- Participants were women aged 18–60 years with major depressive disorder by DSM-5 criteria; all were on standard antidepressant treatment (sertraline or escitalopram), then randomized to l-arginine 1 g twice daily or placebo for 4 weeks.
- Outcomes were assessed at baseline, week 4, and week 8 using Hamilton Depression Rating Scale (HDRS) and FSFI/Rosen’s questionnaire; analysis used intention-to-treat, t-test/Mann-Whitney, chi-square/Fisher’s exact tests, and generalized estimating equations (GEE).
Limitations
- The paper states that the Iranian pharmaceutical market lacked high-dose l-arginine products, so the study used the minimum effective dose from prior studies rather than higher doses.
- The authors report recruitment challenges due to cultural considerations in Iran and note that the 8-week timeframe likely discouraged participation in a longer treatment period.
- Evident from the text: the sample was small (n = 32) and the intervention period was short (4 weeks of l-arginine/placebo), which limits precision and the ability to detect modest effects.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
12 Valid · 3 Not valid · 5 Not checked · 26 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Nitric oxide is one of the metabolites of L-arginine, which has many activities in the body, including its role in sexual functions [29].”
§ Effect of l-arginine compared to placebo on sexual function in women with major depressive disorder: a randomized controlled trial > Background Research showed that sexual function is one of the key factors affecting quality of life. This is further supported by studies where nearly half of participants explicitly mentioned its importance to their overall well-being. This relationship is bidirectional; the people with better physical health are more satisfied with their sexual function [1]. Based on the definition of World Health Organization, sexual health can be expressed as follows: “…a state of physical, emotional, mental and social well-being about sexuality; it is not merely the absence of disease, dysfunction or infirmity” [2]. An imperative aspect to bear in mind regarding sexual function is that improper sexual intercourse among partners has the potential to undermine various facets of their relationship [3]. Various methods are used to improve sexual function, and many studies were conducted and are being conducted in this field. The number and types of these studies indicate the importance of this issue among different societies. Studies on the nutrition [4], exercise [5], complementary medicine [6], and even stimulants [7] are among these studies. Contrary to old beliefs, sexual disorders are not exclusive to men, and the prevalence of these disorders in the women is high. This prevalence differs in multiple societies, but this difference does not mean these disorders are minor [8, 9]. The estimated prevalence of sexual problems in women between 2000 and 2019 by data from 21 eligible studies of sexual disorders was 50.75% based on the systematic review and meta-analysis. Furthermore, the prevalence of pain and disorders in arousal, sexual desire, lubrication, orgasm, and sexual satisfaction were calculated as 39.08%, 48.21%, 50.70%, 37.60%, 40.16%, and 35.02%, respectively [10]. One of the influential factors in sexual function, and the occurrence of sexual disorders is the presence of underlying diseases, such as psychiatric disease, especially major depressive disorder [11]. The prevalence of sexual disorders in the patients with major depressive disorder has been reported differently. In some studies, this disorder was reported in nearly half of patients with major depressive disorder [12, 13]. A meta-analysis in 2022 showed that sexual dysfunction is prevalent in females with depressive disorders who are not in the pharmacological treatment. Women with major depressive disorder showed high rates of sexual impairment, including 47.22% for arousal, 65.30% for desire, 36.98% for lubrication, 34.17% for orgasm, and 33.91% for sexual satisfaction [14]. There is still a need for safe, affordable, and easily available remedies, even in cases when women’s sexual problems can be treated with certain pharmaceutical approaches [15, 16]. However, certain antidepressants can cause sexual dysfunction, making it more challenging to address sexual issues in patients also dealing with major depressive disorder [17]. The development of sexual dysfunction following selective serotonin reuptake inhibitor medications was confirmed in women before [18, 19]. This disorder can be seen in different fields, including sexual desire, difficulty in arousal, and anorgasmia [20, 21]. For this reason, one of the most critical challenges to treat depressed patients with selective serotonin reuptake inhibitors is the sexual disorders induced by these medications, and there are few options for managing this complication [22]. It should be mentioned that this problem is one of the primary causes of medication non-adherence in patients with depression [23]. According to some research, L-arginine may improve sexual function and have a positive impact on the cellular and molecular processes underlying Major Depressive Disorder [24–26]. Based on some animal studies, using L-arginine has reduced depression and related biological signals [27, 28]. Nitric oxide synthase is involved in the production of nitric oxide. Nitric oxide is one of the metabolites of L-arginine, which has many activities in the body, including its role in sexual functions [29]. In the women with sexual dysfunction, a much lower level of nitric oxide synthase was reported in the epithelium of the female genital tract compared to women without sexual dysfunction, which means decreased nitric oxide in those patients [30]. . Previous studies on the effectiveness of L-arginine in treating sexual disorders in men were conducted, and promising results reported [31–33].
What the sources say
- Partly supportedcites [29] Król M, Kepinska M. Human nitric oxide synthase—its functions, polymorphisms, and inhibitors in the context of inflammation, diabetes and cardiovascular diseases. Int J Mol Sci. 2020;22(1):56. sourceExperimental — accuracy not yet measured
Section 2, “Characteristics of NO and Its Derivatives” (page unavailable), says NO is formed from arginine by nitric oxide synthase. Section 5, “Selected NOS Inhibitors and Their Role in Therapy” (page unavailable), describes NO’s role in genitourinary neurotransmission, but the passages do not specifically address sexual functions. (LLM, conf=0.83)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The development of sexual dysfunction following selective serotonin reuptake inhibitor medications was confirmed in women before [18, 19].”
§ Effect of l-arginine compared to placebo on sexual function in women with major depressive disorder: a randomized controlled trial > Background Research showed that sexual function is one of the key factors affecting quality of life. This is further supported by studies where nearly half of participants explicitly mentioned its importance to their overall well-being. This relationship is bidirectional; the people with better physical health are more satisfied with their sexual function [1]. Based on the definition of World Health Organization, sexual health can be expressed as follows: “…a state of physical, emotional, mental and social well-being about sexuality; it is not merely the absence of disease, dysfunction or infirmity” [2]. An imperative aspect to bear in mind regarding sexual function is that improper sexual intercourse among partners has the potential to undermine various facets of their relationship [3]. Various methods are used to improve sexual function, and many studies were conducted and are being conducted in this field. The number and types of these studies indicate the importance of this issue among different societies. Studies on the nutrition [4], exercise [5], complementary medicine [6], and even stimulants [7] are among these studies. Contrary to old beliefs, sexual disorders are not exclusive to men, and the prevalence of these disorders in the women is high. This prevalence differs in multiple societies, but this difference does not mean these disorders are minor [8, 9]. The estimated prevalence of sexual problems in women between 2000 and 2019 by data from 21 eligible studies of sexual disorders was 50.75% based on the systematic review and meta-analysis. Furthermore, the prevalence of pain and disorders in arousal, sexual desire, lubrication, orgasm, and sexual satisfaction were calculated as 39.08%, 48.21%, 50.70%, 37.60%, 40.16%, and 35.02%, respectively [10]. One of the influential factors in sexual function, and the occurrence of sexual disorders is the presence of underlying diseases, such as psychiatric disease, especially major depressive disorder [11]. The prevalence of sexual disorders in the patients with major depressive disorder has been reported differently. In some studies, this disorder was reported in nearly half of patients with major depressive disorder [12, 13]. A meta-analysis in 2022 showed that sexual dysfunction is prevalent in females with depressive disorders who are not in the pharmacological treatment. Women with major depressive disorder showed high rates of sexual impairment, including 47.22% for arousal, 65.30% for desire, 36.98% for lubrication, 34.17% for orgasm, and 33.91% for sexual satisfaction [14]. There is still a need for safe, affordable, and easily available remedies, even in cases when women’s sexual problems can be treated with certain pharmaceutical approaches [15, 16]. However, certain antidepressants can cause sexual dysfunction, making it more challenging to address sexual issues in patients also dealing with major depressive disorder [17]. The development of sexual dysfunction following selective serotonin reuptake inhibitor medications was confirmed in women before [18, 19]. This disorder can be seen in different fields, including sexual desire, difficulty in arousal, and anorgasmia [20, 21]. For this reason, one of the most critical challenges to treat depressed patients with selective serotonin reuptake inhibitors is the sexual disorders induced by these medications, and there are few options for managing this complication [22]. It should be mentioned that this problem is one of the primary causes of medication non-adherence in patients with depression [23]. According to some research, L-arginine may improve sexual function and have a positive impact on the cellular and molecular processes underlying Major Depressive Disorder [24–26]. Based on some animal studies, using L-arginine has reduced depression and related biological signals [27, 28]. Nitric oxide synthase is involved in the production of nitric oxide. Nitric oxide is one of the metabolites of L-arginine, which has many activities in the body, including its role in sexual functions [29]. In the women with sexual dysfunction, a much lower level of nitric oxide synthase was reported in the epithelium of the female genital tract compared to women without sexual dysfunction, which means decreased nitric oxide in those patients [30]. . Previous studies on the effectiveness of L-arginine in treating sexual disorders in men were conducted, and promising results reported [31–33].
What the sources say
- Supportedcites [18] Jing E, Straw-Wilson K. Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: a narrative literature review. Mental Health Clinician. 2016;6(4):191–6. source
The Introduction reports that SSRIs may cause sexual dysfunction, while distinguishing these effects from sexual difficulties that can precede treatment. The Results section specifically identifies inadequate lubrication in women as a sexual side effect associated with paroxetine, an SSRI. The review therefore supports the claim that sexual dysfunction can develop in women following SSRI treatment. (LLM, conf=0.89)
- Not checked — no full text of the sourcecites [19] Rappek NAM, Sidi H, Kumar J, Kamarazaman S, Das S, Masiran R, et al. Serotonin selective reuptake inhibitors (SSRIs) and female sexual dysfunction (FSD): hypothesis on its association and options of treatment. Curr Drug Targets. 2018;19(12):1352–8. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“As previous studies showed, using L-arginine has no significant patient side effects.”
§ Effect of l-arginine compared to placebo on sexual function in women with major depressive disorder: a randomized controlled trial > Discussion This triple-blind, randomized, clinical trial showed that in the patients suffering from depression receiving standard anti-depressant treatment, 2 g per day of L-arginine in the intervention group improved depression and some domains of sexual performance. Based on the FSFI questionnaire, significant changes were observed in two domains of lubrication and orgasm in L-arginine recipients. When compared to the placebo group, this improvement was not statistically significant. The results of this research showed that taking regular antidepressants might significantly lessen the severity of depression. Still, adding L-arginine did not cause a significant difference between L-arginine and the placebo groups. Therefore, an increase was observed in the Rosen Questionnaire or FSFI score, but this increase was not statistically significant. It did not contribute to a positive interpretation of the effectiveness of L-arginine with the dose used in improving depression and increasing sexual function. This research is the first to assess the impact of L-arginine as a supplemental therapy on the sexual functioning of women with Major Depressive Disorder, according to our evaluation. Previously, using L-arginine as a complementary therapy to improve male sexual function was confirmed in various studies [33, 38]. A systematic review and meta-analysis resulted from a randomized clinical trial that included 540 males with erectile dysfunction, using L-arginine with dosing 1500 to 5000 mg effectively improved erectile dysfunction [32]. In a systematic review in 2021, it was found that the compound containing L-arginine called ArginMax can be effective in the treatment of Hypoactive Sexual Desire Disorder and Related Conditions in Women. Five randomized controlled trials and two nonrandomized studies were identified to meet the inclusion criteria based on this systematic review. Six of the seven studies that were included in this had favorable results, indicating either a rise in the overall mean score of the Female Sexual Function Index or a substantial improvement in several areas within the index. Therefore, one study assessed vaginal pulse amplitude and found a statistically significant increase in a combination treatment group compared to placebo. No significant side effects were reported from these studies [39]. One of the most important causes of sexual dysfunction in women is depression, which has been proven in various studies [40, 41]. Consequently, it is anticipated that sexual function would increase in these individuals with well-managed and treated depression. However, some people have sexual dysfunction as a result of using certain drugs to treat depression. One of the most important drugs for treating Major Depressive Disorder is an SSRI. One of the side effects of SSRIs is sexual dysfunction. Based on some studies, SSRIs-induced sexual dysfunction was observed in 25 to 73% of the patients who use these medications for depression treatment [22]. The interesting point is that this property of SSRIs is used to treat premature ejaculation disorder. Based on a meta-analysis in 2021, SSRI treatment probably improves self-perceived premature ejaculation symptoms [42]. The patients were first treated with either sertraline or escitalopram, and intervention in treating patients using L-arginine or placebo began at the end of the fourth week. Based on the scores obtained from the FSFI questionnaire, in the placebo group, the scores of the patients throughout the study had a decreasing trend, which indicated the sexual complications caused by SSRI medication. Unlike the placebo group, in the patients receiving L- arginine, the FSFI score increased in the eighth week compared to the beginning of the study (P-value = 0.058). Although this increase in scoring compared to the placebo group was not statistically significant, it showed that adding L-arginine to the standard antidepressant treatment of patients can positively affect sexual performance. The impact of SSRIs in creating sexual dysfunction may be linked to the absence of statistically meaningful response in patients when L-arginine was used to improve sexual performance. It seems that L-arginine cannot improve SSRI-induced sexual dysfunction, as statistically significant. In previous studies where L-arginine has shown statistically significant effects on sexual function, the recipients of this agent have no mental disorder and use SSRI medications to treat mental illness. In addition to SSRI-induced sexual dysfunction, the lack of statistical significance of the addition of L-arginine on sexual performance despite the improvement of the FSFI score in the L-arginine group may be that in terms of its lower doses compared to most of the other studies [39]. Among the subdomains of FSFI, the lubrication index showed a significant increase in the L-arginine group in the eighth week compared to the baseline level. It should be noted that this rise was not statistically significant when compared to the placebo group. Additionally, the eighth week of the L-arginine group exhibited a substantial change in the orgasm index compared to the baseline level, however this difference was not statistically significant when compared to the placebo group. Although these changes were not statistically significant, they can create a suitable perspective for further research to obtain better results by removing the limitations of this study, which were mentioned earlier. These findings are consistent with previous studies that showed that using L-arginine in the women can positively affect orgasm and lubrication [43]. However, the increase in sexual desire in women, observed in most of the studies mentioned above following the consumption of L-arginine, was not seen in this study, even compare to different periods in the L-arginine group. Based on a systematic review in 2023, L-arginine and L-lysine are effective therapeutic interventions to reduce anxiety and mental stress [44]. Although some animal studies have suggested that stress, and the resulting brain damage that can lead to depression will be reduced with L-arginine, there are few human studies in this regard [45]. The impact of incorporating L-arginine into the conventional antidepressant therapy, which includes one of the two medications, escitalopram or sertraline, was assessed in this study due to the paucity of research on the efficacy of this amino acid in treating depression. Although using of standard depression treatment could significantly reduce the severity of depression in patients of both groups, adding L-arginine to the treatment regimen of patients did not have a statistically significant effect. Because of genetic differences, laboratory evaluation of L-arginine levels, and its metabolites in the patients may be a guide to better patient assessment. If the levels of different metabolites of L- arginine were evaluated in the patients from the beginning of the study, they could show a better view of the treatment process. Major depressive disorder may arise as a result of variations in the urea and nitric oxide cycles’ concentrations of arginine and its associated catabolic products, including ornithine, citrulline, and argininosuccinate. It seems that conducting an integrated assessment of arginine, and its related catabolic products could potentially aid in predicting the probability of developing Major Depressive Disorder [44]. As previous studies showed, using L-arginine has no significant patient side effects. The study conducted by D Menafra et al. aimed to investigate the effects of L-arginine on penile erectile function in patients with vasculogenic erectile dysfunction. The study was multicenter, double- blind, randomized, and placebo-controlled, with a total of 98 participants (51 on L-arginine and 47 on placebo), and was published in 2022. The participants received a relatively high daily oral dose of 6 g of L-arginine for three months. The study compared the outcomes of mild- moderate and severe vasculogenic erectile dysfunction. The results of the study showed no serious complications reported in patients who received L-arginine [46]. In our study, the patients reported no dangerous side effects or injuries. The only side effect reported in the patients, slightly more than in the placebo group, was gastrointestinal upset. However, these side effects were not statistically significant compared to the placebo group.
What the sources say
- Supportedcites [46] Menafra D, de Angelis C, Garifalos F, Mazzella M, Galdiero G, Piscopo M, et al. Long-term high- dose l-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double- blind, randomized, placebo-controlled clinical trial. J Endocrinol Investig. 2022;45(5):941–61. source
The Discussion reports that a review of previous studies found adverse effects in 2% of patients taking L-arginine alone, with none reported as severe. The Results (Safety) also report adverse events in 5.88% of the L-arginine group in this trial, but none was clinically relevant. Thus the claim is supported if “no significant side effects” means no clinically significant effects, not no side effects at all. (LLM, conf=0.91)
plainn = 98- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This disorder can be seen in different fields, including sexual desire, difficulty in arousal, and anorgasmia [20, 21].”
§ Effect of l-arginine compared to placebo on sexual function in women with major depressive disorder: a randomized controlled trial > Background Research showed that sexual function is one of the key factors affecting quality of life. This is further supported by studies where nearly half of participants explicitly mentioned its importance to their overall well-being. This relationship is bidirectional; the people with better physical health are more satisfied with their sexual function [1]. Based on the definition of World Health Organization, sexual health can be expressed as follows: “…a state of physical, emotional, mental and social well-being about sexuality; it is not merely the absence of disease, dysfunction or infirmity” [2]. An imperative aspect to bear in mind regarding sexual function is that improper sexual intercourse among partners has the potential to undermine various facets of their relationship [3]. Various methods are used to improve sexual function, and many studies were conducted and are being conducted in this field. The number and types of these studies indicate the importance of this issue among different societies. Studies on the nutrition [4], exercise [5], complementary medicine [6], and even stimulants [7] are among these studies. Contrary to old beliefs, sexual disorders are not exclusive to men, and the prevalence of these disorders in the women is high. This prevalence differs in multiple societies, but this difference does not mean these disorders are minor [8, 9]. The estimated prevalence of sexual problems in women between 2000 and 2019 by data from 21 eligible studies of sexual disorders was 50.75% based on the systematic review and meta-analysis. Furthermore, the prevalence of pain and disorders in arousal, sexual desire, lubrication, orgasm, and sexual satisfaction were calculated as 39.08%, 48.21%, 50.70%, 37.60%, 40.16%, and 35.02%, respectively [10]. One of the influential factors in sexual function, and the occurrence of sexual disorders is the presence of underlying diseases, such as psychiatric disease, especially major depressive disorder [11]. The prevalence of sexual disorders in the patients with major depressive disorder has been reported differently. In some studies, this disorder was reported in nearly half of patients with major depressive disorder [12, 13]. A meta-analysis in 2022 showed that sexual dysfunction is prevalent in females with depressive disorders who are not in the pharmacological treatment. Women with major depressive disorder showed high rates of sexual impairment, including 47.22% for arousal, 65.30% for desire, 36.98% for lubrication, 34.17% for orgasm, and 33.91% for sexual satisfaction [14]. There is still a need for safe, affordable, and easily available remedies, even in cases when women’s sexual problems can be treated with certain pharmaceutical approaches [15, 16]. However, certain antidepressants can cause sexual dysfunction, making it more challenging to address sexual issues in patients also dealing with major depressive disorder [17]. The development of sexual dysfunction following selective serotonin reuptake inhibitor medications was confirmed in women before [18, 19]. This disorder can be seen in different fields, including sexual desire, difficulty in arousal, and anorgasmia [20, 21]. For this reason, one of the most critical challenges to treat depressed patients with selective serotonin reuptake inhibitors is the sexual disorders induced by these medications, and there are few options for managing this complication [22]. It should be mentioned that this problem is one of the primary causes of medication non-adherence in patients with depression [23]. According to some research, L-arginine may improve sexual function and have a positive impact on the cellular and molecular processes underlying Major Depressive Disorder [24–26]. Based on some animal studies, using L-arginine has reduced depression and related biological signals [27, 28]. Nitric oxide synthase is involved in the production of nitric oxide. Nitric oxide is one of the metabolites of L-arginine, which has many activities in the body, including its role in sexual functions [29]. In the women with sexual dysfunction, a much lower level of nitric oxide synthase was reported in the epithelium of the female genital tract compared to women without sexual dysfunction, which means decreased nitric oxide in those patients [30]. . Previous studies on the effectiveness of L-arginine in treating sexual disorders in men were conducted, and promising results reported [31–33].
What the sources say
- Supportedcites [20] Healy D. Citizen petition: sexual side effects of SSRIs and SNRIs. Int J Risk Saf Med. 2018;29(3–4):135. source
The Statement of grounds section on persistent sexual side effects after stopping medication describes SSRI-associated loss of libido, erectile dysfunction, and anorgasmia. Erectile dysfunction is an example of difficulty with arousal, so the cited paper supports all three types of difficulty named in the claim. (LLM, conf=0.92)
- Supportedcites [21] Moses TE, Javanbakht A. Resolution of selective serotonin reuptake inhibitor–Associated sexual dysfunction after switching from fluvoxamine to Fluoxetine. J Clin Psychopharmacol. 2023;43(1):71. source
The “To the Editors” section identifies loss of libido, arousal disorders, and orgasm disorders as the three main types of sexual dysfunction, in its discussion of SSRI-associated adverse effects. The Discussion also states that SSRIs may impair sexual drive, arousal, and sexual satiety. The claim is a fair paraphrase; no page number is provided in our copy. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“One of the most important causes of sexual dysfunction in women is depression, which has been proven in various studies [40, 41].”
§ Effect of l-arginine compared to placebo on sexual function in women with major depressive disorder: a randomized controlled trial > Discussion This triple-blind, randomized, clinical trial showed that in the patients suffering from depression receiving standard anti-depressant treatment, 2 g per day of L-arginine in the intervention group improved depression and some domains of sexual performance. Based on the FSFI questionnaire, significant changes were observed in two domains of lubrication and orgasm in L-arginine recipients. When compared to the placebo group, this improvement was not statistically significant. The results of this research showed that taking regular antidepressants might significantly lessen the severity of depression. Still, adding L-arginine did not cause a significant difference between L-arginine and the placebo groups. Therefore, an increase was observed in the Rosen Questionnaire or FSFI score, but this increase was not statistically significant. It did not contribute to a positive interpretation of the effectiveness of L-arginine with the dose used in improving depression and increasing sexual function. This research is the first to assess the impact of L-arginine as a supplemental therapy on the sexual functioning of women with Major Depressive Disorder, according to our evaluation. Previously, using L-arginine as a complementary therapy to improve male sexual function was confirmed in various studies [33, 38]. A systematic review and meta-analysis resulted from a randomized clinical trial that included 540 males with erectile dysfunction, using L-arginine with dosing 1500 to 5000 mg effectively improved erectile dysfunction [32]. In a systematic review in 2021, it was found that the compound containing L-arginine called ArginMax can be effective in the treatment of Hypoactive Sexual Desire Disorder and Related Conditions in Women. Five randomized controlled trials and two nonrandomized studies were identified to meet the inclusion criteria based on this systematic review. Six of the seven studies that were included in this had favorable results, indicating either a rise in the overall mean score of the Female Sexual Function Index or a substantial improvement in several areas within the index. Therefore, one study assessed vaginal pulse amplitude and found a statistically significant increase in a combination treatment group compared to placebo. No significant side effects were reported from these studies [39]. One of the most important causes of sexual dysfunction in women is depression, which has been proven in various studies [40, 41]. Consequently, it is anticipated that sexual function would increase in these individuals with well-managed and treated depression. However, some people have sexual dysfunction as a result of using certain drugs to treat depression. One of the most important drugs for treating Major Depressive Disorder is an SSRI. One of the side effects of SSRIs is sexual dysfunction. Based on some studies, SSRIs-induced sexual dysfunction was observed in 25 to 73% of the patients who use these medications for depression treatment [22]. The interesting point is that this property of SSRIs is used to treat premature ejaculation disorder. Based on a meta-analysis in 2021, SSRI treatment probably improves self-perceived premature ejaculation symptoms [42]. The patients were first treated with either sertraline or escitalopram, and intervention in treating patients using L-arginine or placebo began at the end of the fourth week. Based on the scores obtained from the FSFI questionnaire, in the placebo group, the scores of the patients throughout the study had a decreasing trend, which indicated the sexual complications caused by SSRI medication. Unlike the placebo group, in the patients receiving L- arginine, the FSFI score increased in the eighth week compared to the beginning of the study (P-value = 0.058). Although this increase in scoring compared to the placebo group was not statistically significant, it showed that adding L-arginine to the standard antidepressant treatment of patients can positively affect sexual performance. The impact of SSRIs in creating sexual dysfunction may be linked to the absence of statistically meaningful response in patients when L-arginine was used to improve sexual performance. It seems that L-arginine cannot improve SSRI-induced sexual dysfunction, as statistically significant. In previous studies where L-arginine has shown statistically significant effects on sexual function, the recipients of this agent have no mental disorder and use SSRI medications to treat mental illness. In addition to SSRI-induced sexual dysfunction, the lack of statistical significance of the addition of L-arginine on sexual performance despite the improvement of the FSFI score in the L-arginine group may be that in terms of its lower doses compared to most of the other studies [39]. Among the subdomains of FSFI, the lubrication index showed a significant increase in the L-arginine group in the eighth week compared to the baseline level. It should be noted that this rise was not statistically significant when compared to the placebo group. Additionally, the eighth week of the L-arginine group exhibited a substantial change in the orgasm index compared to the baseline level, however this difference was not statistically significant when compared to the placebo group. Although these changes were not statistically significant, they can create a suitable perspective for further research to obtain better results by removing the limitations of this study, which were mentioned earlier. These findings are consistent with previous studies that showed that using L-arginine in the women can positively affect orgasm and lubrication [43]. However, the increase in sexual desire in women, observed in most of the studies mentioned above following the consumption of L-arginine, was not seen in this study, even compare to different periods in the L-arginine group. Based on a systematic review in 2023, L-arginine and L-lysine are effective therapeutic interventions to reduce anxiety and mental stress [44]. Although some animal studies have suggested that stress, and the resulting brain damage that can lead to depression will be reduced with L-arginine, there are few human studies in this regard [45]. The impact of incorporating L-arginine into the conventional antidepressant therapy, which includes one of the two medications, escitalopram or sertraline, was assessed in this study due to the paucity of research on the efficacy of this amino acid in treating depression. Although using of standard depression treatment could significantly reduce the severity of depression in patients of both groups, adding L-arginine to the treatment regimen of patients did not have a statistically significant effect. Because of genetic differences, laboratory evaluation of L-arginine levels, and its metabolites in the patients may be a guide to better patient assessment. If the levels of different metabolites of L- arginine were evaluated in the patients from the beginning of the study, they could show a better view of the treatment process. Major depressive disorder may arise as a result of variations in the urea and nitric oxide cycles’ concentrations of arginine and its associated catabolic products, including ornithine, citrulline, and argininosuccinate. It seems that conducting an integrated assessment of arginine, and its related catabolic products could potentially aid in predicting the probability of developing Major Depressive Disorder [44]. As previous studies showed, using L-arginine has no significant patient side effects. The study conducted by D Menafra et al. aimed to investigate the effects of L-arginine on penile erectile function in patients with vasculogenic erectile dysfunction. The study was multicenter, double- blind, randomized, and placebo-controlled, with a total of 98 participants (51 on L-arginine and 47 on placebo), and was published in 2022. The participants received a relatively high daily oral dose of 6 g of L-arginine for three months. The study compared the outcomes of mild- moderate and severe vasculogenic erectile dysfunction. The results of the study showed no serious complications reported in patients who received L-arginine [46]. In our study, the patients reported no dangerous side effects or injuries. The only side effect reported in the patients, slightly more than in the placebo group, was gastrointestinal upset. However, these side effects were not statistically significant compared to the placebo group.
What the sources say
- Partly supportedcites [40] Reddy RM, Saravanan RA, Praharaj SK, Thirunavukarasu M. Sexual dysfunction in women with depression: a hospital-based cross-sectional comparative study. Indian J Psychol Med. 2020;42(1):46–51. sourceExperimental — accuracy not yet measured
The paper's introduction says earlier studies suggested depression increases the risk of female sexual dysfunction, and its Results report significantly more dysfunction among women with depression than controls. That supports a link, but this cross-sectional study does not establish that depression is a cause, let alone one of the most important causes. (LLM, conf=0.88)
- Partly supportedcites [41] Basson R, Gilks T. Women’s sexual dysfunction associated with psychiatric disorders and their treatment. Women’s Health. 2018;14:1745506518762664. sourceExperimental — accuracy not yet measured
The Introduction calls psychiatric disease the most important risk factor for women’s sexual dysfunction and identifies depression as strongly associated with it. But the Introduction also says the causal pathway is debated, so the source does not establish depression as a proven cause. (LLM, conf=0.86)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
18 more claims
Create a free account to see all 46 claims and every source verdict.
- Probably not a substantial claim. 13
- It may state two separate claims as one. 11
- The quote only partly states this claim. 2
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Based on some animal studies, using L-arginine has reduced depression and related biological signals [27, 28].”
Cited work 10.1016/j.brainresbull.2020.02.014 · retracted 2020-07-17 · notice 10.1016/j.brainresbull.2020.07.002 · this paper published 2024-05-14
Citations
Cites
1 retracted
Dong, D., Lei, T., Song, M., Ma, L., & Zhao, H. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.02.014 · Cited by 13 · cited 1×
“Based on some animal studies, using L-arginine has reduced depression and related biological signals [27, 28].”
ResultRetractedFlynn, K. E., Lin, L., Bruner, D. W., Cyranowski, J. M., Hahn, E. A., Jeffery, D. D., Reese, J. B., Reeve, B. B., Shelby, R. A., & Weinfurt, K. P. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2016.08.011 · Cited by 528 · cited 1×
“This relationship is bidirectional; the people with better physical health are more satisfied with their sexual function [1].”
BackgroundAntidepressant‐induced sexual dysfunction
Rothmore, J. (2020) · Medical Journal of Australia · doi:10.5694/mja2.50522 · Cited by 229 · cited 1×
“It should be mentioned that this problem is one of the primary causes of medication non-adherence in patients with depression [23].”
BackgroundWomen’s sexual dysfunction associated with psychiatric disorders and their treatment
Basson, R., & Gilks, T. (2018) · Women's Health · doi:10.1177/1745506518762664 · Cited by 225 · cited 1×
“One of the most important causes of sexual dysfunction in women is depression, which has been proven in various studies [40, 41].”
ResultSexual health, sexual rights and sexual pleasure: meaningfully engaging the perfect triangle
Gruskin, S., Yadav, V., Castellanos-Usigli, A., Khizanishvili, G., & Kismödi, E. (2019) · Sexual and Reproductive Health Matters · doi:10.1080/26410397.2019.1593787 · Cited by 212 · cited 1×
“Based on the definition of World Health Organization, sexual health can be expressed as follows: “…a state of physical, emotional, mental and social well-being about sexuality; it is not merely the absence of disease, dysfunction or infirmity” [2].”
MethodKról, M., & Kepinska, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010056 · Cited by 187 · cited 1×
“Nitric oxide is one of the metabolites of L-arginine, which has many activities in the body, including its role in sexual functions [29].”
BackgroundPhysical activity and exercise for erectile dysfunction: systematic review and meta-analysis
Silva, A. B., Sousa, N., Azevedo, L. F., & Martins, C. (2016) · British Journal of Sports Medicine · doi:10.1136/bjsports-2016-096418 · Cited by 144 · cited 1×
“Studies on the nutrition [4], exercise [5], complementary medicine [6], and even stimulants [7] are among these studies.”
BackgroundJing, E., & Straw-Wilson, K. (2016) · Mental Health Clinician · doi:10.9740/mhc.2016.07.191 · Cited by 121 · cited 1×
“The development of sexual dysfunction following selective serotonin reuptake inhibitor medications was confirmed in women before [18, 19].”
BackgroundLa, J., Roberts, N. H., & Yafi, F. A. (2017) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2017.07.004 · Cited by 121 · cited 1×
“Studies on the nutrition [4], exercise [5], complementary medicine [6], and even stimulants [7] are among these studies.”
BackgroundExploring the Effects of Sexual Desire Discrepancy Among Married Couples
Willoughby, B. J., Farero, A. M., & Busby, D. M. (2013) · Archives of Sexual Behavior · doi:10.1007/s10508-013-0181-2 · Cited by 104 · cited 1×
“An imperative aspect to bear in mind regarding sexual function is that improper sexual intercourse among partners has the potential to undermine various facets of their relationship [3].”
Background
Research works printed but not linked: 1
- Menafra D, de Angelis C, Garifalos F, Mazzella M, Galdiero G, Piscopo M, et al. Long-term high- dose l-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double- blind, randomized, placebo-controlled clinical trial. J Endocrinol Investig. 2022;45(5):941–61. · DOI · Paper page
Cited by
Meftah, N., Fakheri, F., Moudi, M., & Shirafkan, H. (2026) · Research Square · doi:10.21203/rs.3.rs-10775435/v1
Metadata
- Authors
- Torkaman, P., Meybodi, A. M., Kheradmand, A., Eiliaei, S., & Ardakani, M. T.
- Affiliations
- Shahid Beheshti University (IR)
- Taleghani General Hospital (IR)
- Corresponding author
- Ardakani, Maria Tavakoli
- Venue
- BMC Psychiatry
- Published
- 2024-05-14
- Volume
- 24
- Issue
- 1
- Pages
- 358-358
- ISSN
- 1471-244X (ISSN-L)
- PMC
- PMC11092258
- OpenAlex
- W4396894568
- Cited by
- 1
- References
- 47
- Citations by year
- 2026: 1
- FWCI
- 0.29
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- BMC Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Shahid Beheshti University of Medical Sciences
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Sexuality, Behavior, and Technology
- Keywords
- L-arginine, major depressive disorder, female sexual function, women with depression, sexual lubrication, orgasm, depression severity, dietary supplementation
- MeSH terms
- Adult, Arginine, Major Depressive Disorder, Double-Blind Method, Female, Humans, Middle Aged, Sexual Behavior, Sexual Dysfunction, Physiological, Treatment Outcome, Sexual Dysfunctions, Psychological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of l-arginine compared to placebo on sexual function in women with major depressive disorder: a randomized controlled trial. https://app.cochat.ai/papers/10.1186/s12888-024-05781-5
- The paper
- Torkaman, P., Meybodi, A. M., Kheradmand, A., Eiliaei, S., & Ardakani, M. T. (2024). Effect of l-arginine compared to placebo on sexual function in women with major depressive disorder: a randomized controlled trial. BMC Psychiatry. https://doi.org/10.1186/s12888-024-05781-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
